Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Replimune Group Inc (REPL)

Replimune Group Inc (REPL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Thu Dec 18, 7:00AM CST

WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 9.88 (+1.96%)
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) GlobeNewswire - Fri Nov 7, 3:45PM CST

WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 9.88 (+1.96%)
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire - Thu Nov 6, 7:00AM CST

WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 9.88 (+1.96%)
Author
The Best AI for Picking Stocks, Ranked by Performance MarketBeat - Wed Oct 22, 4:47PM CDT

AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period.

SOUN : 11.02 (+1.19%)
SMCI : 31.11 (+5.92%)
HUT : 44.12 (+14.33%)
MLTX : 13.39 (+0.98%)
LRMR : 3.65 (+6.41%)
REPL : 9.88 (+1.96%)
ASTS : 75.84 (+15.03%)
RGC : 19.81 (+4.70%)
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma GlobeNewswire - Mon Oct 20, 6:00AM CDT

WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 9.88 (+1.96%)
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 GlobeNewswire - Sun Oct 19, 7:00AM CDT

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 9.88 (+1.96%)
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 GlobeNewswire - Sun Oct 19, 7:00AM CDT

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...

REPL : 9.88 (+1.96%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL PR Newswire - Tue Sep 23, 9:00AM CDT

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL)....

REPL : 9.88 (+1.96%)
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune Business Wire - Mon Sep 22, 1:24PM CDT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their...

REPL : 9.88 (+1.96%)
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm PR Newswire - Mon Sep 22, 10:06AM CDT

NEW YORK , Sept. 22, 2025 /PRNewswire/ --

REPL : 9.88 (+1.96%)

Barchart Exclusives

5 "Best of the Best" Dividend Stocks to Own in 2026 Barchart - Fri Dec 19, 6:00PM CST
These five companies come with above-average yields and buy ratings from Wall Street analysts. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot